Skip to main content Back to Top
Advertisement

4/25/2017

Atropine Sulfate Ophthalmic Solution

Products Affected - Description

    • Isopto Atropine ophthalmic solution, Alcon Labs, 1%, 15 mL bottle, 1 count, NDC 00998-0303-15
    • Isopto Atropine ophthalmic solution, Alcon Labs, 1%, 5 mL bottle, 1 count, NDC 00998-0303-05
    • Atropine Sulfate ophthalmic solution, Akorn, 1%, 15 mL bottle, 1 count, NDC 17478-0214-12
    • Atropine Sulfate ophthalmic solution, Akorn, 1%, 2 mL bottle, 1 count, NDC 17478-0214-20
    • Atropine Sulfate ophthalmic solution, Akorn, 1%, 5 mL bottle, 1 count, NDC 17478-0214-10
    • Atropine Sulfate ophthalmic solution, Sandoz, 1%, 15 mL bottle, 1 count, NDC 61314-0303-02
    • Atropine Sulfate ophthalmic solution, Sandoz, 1%, 5 mL bottle, 1 count, NDC 61314-0303-01
    • Atropine Sulfate ophthalmic solution, Valeant, 1%, 15 mL bottle, 1 count, NDC 24208-0750-06
    • Atropine Sulfate ophthalmic solution, Valeant, 1%, 5 mL bottle, 1 count, NDC 24208-0750-60

Reason for the Shortage

    • Alcon has discontinued Isopto Atropine.
    • Akorn received FDA approval for atropine sulfate 1% ophthalmic solution in July 2014; this new product launched in January 2015.
    • Sandoz has discontinued atropine sulfate ophthalmic solution.
    • Valeant discontinued their atropine sulfate 1% ophthalmic solution products in 2015.

Available Products

    • Atropine Sulfate ophthalmic solution, Akorn, 1%, 15 mL bottle, 1 count, NDC 17478-0215-15
    • Atropine Sulfate ophthalmic solution, Akorn, 1%, 2 mL bottle, 1 count, NDC 17478-0215-02
    • Atropine Sulfate ophthalmic solution, Akorn, 1%, 5 mL bottle, 1 count, NDC 17478-0215-05

Estimated Resupply Dates

    • Akorn has atropine sulfate ophthalmic solution available.

Updated

Updated April 25, 2017 by Michelle Wheeler, PharmD, Drug Information Specialist. Created November 21, 2014 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins